National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

Bill: 116-hr-4866
Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6]
Introduced: 2019-10-28 in the House
Policy area: Health
Subjects: Advanced technology and technological innovations
Congressional oversight
Drug safety, medical device, and laboratory regulation
Government information and archives
Health programs administration and funding
Health technology, devices, supplies
Higher education
Manufacturing
Prescription drugs
Product development and innovation
Research administration and funding
Research and development

Summary:
action_date: 2019-10-28
text: 

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019

 
This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

action_date: 2020-09-21
text: 

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

 
This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)


Legislative actions:
action_date: 2020-09-22
text: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
action_date: 2020-09-21
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2020-09-21
text: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)
action_date: 2020-09-21
text: Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
action_date: 2020-09-21
text: DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.
action_date: 2020-09-21
text: Considered under suspension of the rules. (consideration: CR H4616-4618)
action_date: 2020-09-21
text: Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
action_date: 2020-09-17
text: Placed on the Union Calendar, Calendar No. 413.
action_date: 2020-09-17
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
action_date: 2020-09-17
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
action_date: 2020-07-15
text: Ordered to be Reported (Amended) by Voice Vote.
action_date: 2020-07-15
text: Committee Consideration and Mark-up Session Held.
action_date: 2020-03-11
text: Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
action_date: 2020-03-11
text: Subcommittee Consideration and Mark-up Session Held.
action_date: 2019-10-29
text: Referred to the Subcommittee on Health.
action_date: 2019-10-28
text: Referred to the House Committee on Energy and Commerce.
action_date: 2019-10-28
text: Introduced in House
action_date: 2019-10-28
text: Introduced in House